BRD0418
Based on 1 Customer Validation
BRD0418 is a diversity-oriented synthesis (DOS) molecule that regulates the expression of tribbles pseudokinase 1. BRD0418 has the effect of causing hot lipoprotein metabolism from fat production to clearance. BRD0418 can be used in the study of coronary artery disease (CAD) .
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.22%
- CAS. Nr.: 1565827-99-7
- Formel: C29H32N2O5
- Molecular Weight:488.57
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Chemical Information
-
CAS. Nr. 1565827-99-7
-
Appearance Solid
-
Molecular Weight 488.57
-
Formel C29H32N2O5
-
Color Light yellow to yellow
-
SMILES
O=C(C[C@@H]1C[C@@]2([C@@]([H])(OC3=CC=C(C=C23)N(C)C)[C@@H](O1)CO)[H])NCC4=CC=C(C=C4)OC5=CC=CC=C5
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 50 mg/mL (102.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
Reinheit & Dokumentation
-
Data Sheet (269 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0468 mL | 10.2339 mL | 20.4679 mL | 51.1697 mL |
| 5 mM | 0.4094 mL | 2.0468 mL | 4.0936 mL | 10.2339 mL | |
| 10 mM | 0.2047 mL | 1.0234 mL | 2.0468 mL | 5.1170 mL | |
| 15 mM | 0.1365 mL | 0.6823 mL | 1.3645 mL | 3.4113 mL | |
| 20 mM | 0.1023 mL | 0.5117 mL | 1.0234 mL | 2.5585 mL | |
| 25 mM | 0.0819 mL | 0.4094 mL | 0.8187 mL | 2.0468 mL | |
| 30 mM | 0.0682 mL | 0.3411 mL | 0.6823 mL | 1.7057 mL | |
| 40 mM | 0.0512 mL | 0.2558 mL | 0.5117 mL | 1.2792 mL | |
| 50 mM | 0.0409 mL | 0.2047 mL | 0.4094 mL | 1.0234 mL | |
| 60 mM | 0.0341 mL | 0.1706 mL | 0.3411 mL | 0.8528 mL | |
| 80 mM | 0.0256 mL | 0.1279 mL | 0.2558 mL | 0.6396 mL | |
| 100 mM | 0.0205 mL | 0.1023 mL | 0.2047 mL | 0.5117 mL |